Patents by Inventor Murray Robinson
Murray Robinson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210395779Abstract: The present invention provides two-gene retroviral vector compositions comprising polynucleotides encoding an anti-CD7 chimeric activating receptor (CAR) and polynucleotides encoding an anti-CD7 protein expression blocker. Also provided are methods of producing and methods of using such compositions in cancer therapy.Type: ApplicationFiled: November 14, 2019Publication date: December 23, 2021Inventors: Rizal Ismail, Yunqin Lee, Murray Robinson, Ying Xim Tan
-
Patent number: 9896730Abstract: The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further provides methods for treating patients with cancer that incorporate these methods.Type: GrantFiled: April 25, 2012Date of Patent: February 20, 2018Assignees: OSI Pharmaceuticals, LLC, AVEO PHARMACEUTICALS, INC.Inventors: Julie Kan, Stuart Thomson, Gretchen M. Argast, Matthew E. O'Connor, Murray Robinson, Bin Feng, Joerg Heyer, Maria I. Chiu, Richard Nicoletti
-
Patent number: 9345788Abstract: A reconstituted human breast tumor model is disclosed. The model, which is incorporated into mice, provides actual tumors that arise spontaneously, thereby mimicking naturally occurring breast cancer. The tumors are genetically human, because they arise from human mammary tissues that develop from human mammary epithelial cells implanted into host mice. Prior to implantation, the mammary epithelial cells are genetically modified to contain a recombinant human oncogene and an SV40 early region.Type: GrantFiled: June 28, 2005Date of Patent: May 24, 2016Assignee: AVEO Pharmaceuticals, Inc.Inventors: Min Wu, Charlotte Kuperwasser, Murray Robinson
-
Publication number: 20140045715Abstract: A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry.Type: ApplicationFiled: August 5, 2013Publication date: February 13, 2014Applicant: AVEO PHARMACEUTICALS, INC.Inventors: Jie Lin, Bin Feng, Murray Robinson, Feng Jiang, Xiaojian Sun
-
Patent number: 8373017Abstract: Reconstituted human breast tumor models are disclosed. The models, which are incorporated into mice, provide actual tumors that arise spontaneously, thereby mimicking naturally occurring breast cancer. The tumors are genetically human, because they arise from human mammary tissues that develop from human mammary epithelial cells implanted into host mice. Prior to implantation, the mammary epithelial cells are genetically modified to contain either: (a) a recombinant human oncogene and an SV40er; or (b) a recombinant human oncogene, a transgene or shRNA that inhibits the p53 pathway, and a transgene or shRNA that inhibits the Rb pathway.Type: GrantFiled: December 6, 2005Date of Patent: February 12, 2013Assignee: AVEO Pharmaceuticals, Inc.Inventors: Min Wu, Charlotte Kuperwasser, Murray Robinson
-
Publication number: 20120302572Abstract: The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further provides methods for treating patients with cancer that incorporate these methods.Type: ApplicationFiled: April 25, 2012Publication date: November 29, 2012Applicants: AVEO PHARMACEUTICALS, INC., OSI Pharmaceuticals, LLCInventors: Julie Kan, Stuart Thomson, Gretchen M. Argast, Matthew E. O'Connor, Murray Robinson, Bin Feng, Joerg Heyer, Maria I. Chiu, Richard Nicoletti
-
Publication number: 20120231478Abstract: A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry.Type: ApplicationFiled: June 3, 2010Publication date: September 13, 2012Inventors: Jie Lin, Bin Feng, Murray Robinson, Feng Jiang, Xiaojian Sun
-
Patent number: 7928520Abstract: A microfabricated structure that includes a first layer of material on a substrate, and a second layer of material over the first layer that forms an encapsulated cavity, and a structural support layer added to the second layer. Openings can be formed in the cavity, and the cavities can be layered side by side, vertically stacked with interconnections via the openings, and a combination of both can be used to construct stacked arrays with interconnections throughout.Type: GrantFiled: January 12, 2010Date of Patent: April 19, 2011Assignee: STMicroelectronics, Inc.Inventors: Frank Bryant, Murray Robinson
-
Patent number: 7736861Abstract: A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry.Type: GrantFiled: December 22, 2009Date of Patent: June 15, 2010Assignee: AVEO Pharmaceuticals, Inc.Inventors: Jie Lin, Bin Feng, Murray Robinson, Feng Jiang, Xiaojian Sun
-
Publication number: 20100109100Abstract: A microfabricated structure that includes a first layer of material on a substrate, and a second layer of material over the first layer that forms an encapsulated cavity, and a structural support layer added to the second layer. Openings can be formed in the cavity, and the cavities can be layered side by side, vertically stacked with interconnections via the openings, and a combination of both can be used to construct stacked arrays with interconnections throughout.Type: ApplicationFiled: January 12, 2010Publication date: May 6, 2010Applicant: STMICROELECTRONICS, INC.Inventors: Frank Bryant, Murray Robinson
-
Patent number: 7666798Abstract: A microfabricated structure and method of making that includes forming a first layer of material on a substrate, forming patterned sacrificial material having a predetermined shape on the first layer of material, and forming a second layer of material over the first layer and the patterned sacrificial material, which is then removed to form an encapsulated cavity. Ideally, the first and second layers are formed of the same type material. A structural support layer can be added to the second layer. Openings can be formed in the cavity, and the cavities can be layered side by side, vertically stacked with interconnections via the openings, and a combination of both can be used to construct stacked arrays with interconnections throughout.Type: GrantFiled: May 24, 2006Date of Patent: February 23, 2010Assignee: STMicroelectronics, Inc.Inventors: Frank Bryant, Murray Robinson
-
Patent number: 7622630Abstract: Chimeric nonhuman mammals useful as inducible spontaneous cancer models are disclosed. The nonhuman mammals are obtained by introducing one or more genetically modified embryonic stem (ES) cells into an early stage embryo, and then implanting the manipulated embryo into a surrogate mother. The ES cells contain a recombinant oncogene, and also may contain a genetic mutation that deletes or inactivates a tumor suppressor gene. Models of different types of cancer are produced by introducing different combinations of genetic mutations into the ES cells that are introduced into the early stage embryo.Type: GrantFiled: August 27, 2004Date of Patent: November 24, 2009Assignee: AVEO Pharmaceuticals, Inc.Inventors: Joerg Heyer, Murray Robinson, William Rideout, III, Ronald Depinho, Steven C. Clark, Yinghui Zhou, Tyler Jacks, Ronan C. O'Hagan
-
Patent number: 7615353Abstract: A diagnostic method for predicting quantitatively whether a human tumor will be responsive or resistant (non-responsive) to treatment with the VEGF inhibitor, tivozanib (AV-951), is disclosed. The test is based on application of an algorithm to measurements of expression levels of the genes in a predictive gene set.Type: GrantFiled: July 6, 2009Date of Patent: November 10, 2009Assignee: AVEO Pharmaceuticals, Inc.Inventors: Jie Lin, Murray Robinson, Bin Feng, Wenping Kathryn Sun
-
Patent number: 7556796Abstract: A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary and sufficient for the tumorigenicity of the tumorigenic mouse cell, and (ii) the inducible promoter is in the uninduced state; and (b) introducing into the cell a recombinant gene of interest that functionally complements the oncogene, thereby restoring tumorigenicity without expression of the inducible recombinant oncogene. Also disclosed is a method of testing a compound for anti-tumor effects.Type: GrantFiled: April 5, 2006Date of Patent: July 7, 2009Assignee: AVEO Pharmaceuticals, Inc.Inventors: Murray Robinson, Ronan O'Hagan, Karuppiah Kannan, Ti Cai, Maria Isabel Chiu, Lorena Lerner, Jie Lin, Yinghui Zhou
-
Publication number: 20090165150Abstract: The invention provides an improved directed complementation method for generating a conditionally tumorigenic mouse cell. In a directed complementation method, the tumorigenicity of a conditionally tumorigenic mouse cell depends on either the expression of an inducible recombinant oncogene or the expression of a recombinant gene of interest that functionally complements an uninduced recombinant oncogene. The invention provides a method of producing a tumorigenic mouse cell containing an uninduced oncogene, a recombinant gene of interest that functionally complements the uninduced oncogene, and a Cre-ER system capable of excising the recombinant gene of interest. When the Cre-ER system is activated, the recombinant gene of interest is excised. From the effect on the mouse cell it is possible to determine whether the recombinant gene of interest is a tumor maintenance gene.Type: ApplicationFiled: December 21, 2007Publication date: June 25, 2009Inventors: Yinghui Zhou, William Rideout, III, Joerg Heyer, Murray Robinson
-
Publication number: 20080234304Abstract: The invention provides methods using N3-pyridyl-thiamine compounds and pharmaceutical compositions comprising N3-pyridyl-thiamine, which are especially useful for preventing or reducing tumor growth in vivo. The invention is also directed to the benefits of reducing thiamine concentrations, e.g., by means of a thiamine reduced diet, as an effective step in a therapeutic regime for patients treated with N3-pyridyl-thiamine.Type: ApplicationFiled: March 23, 2005Publication date: September 25, 2008Applicant: AVEO PHARMACEUTICALS, INC.Inventors: Jeno Gyuris, Ronan C. O'Hagan, May Han, Murray Robinson, Solly Weiler
-
Publication number: 20070292948Abstract: Chimeric nonhuman mammals useful as inducible spontaneous cancer models are disclosed. The nonhuman mammals are obtained by introducing one or more genetically modified embryonic stem (ES) cells into an early stage embryo, and then implanting the manipulated embryo into a surrogate mother. The ES cells contain a recombinant oncogene, and also may contain a genetic mutation that deletes or inactivates a tumor suppressor gene. Models of different types of cancer are produced by introducing different combinations of genetic mutations into the ES cells that are introduced into the early stage embryo.Type: ApplicationFiled: August 27, 2004Publication date: December 20, 2007Applicant: GEN-PATH PHARMACEUTICALS, INCInventors: Joerg Heyer, Murray Robinson, William Rideout, Ronald Depinho, Steven Clark, Yinghui Zhou, Tyler Jacks
-
Publication number: 20070273728Abstract: A microfabricated structure and method of making that includes forming a first layer of material on a substrate, forming patterned sacrificial material having a predetermined shape on the first layer of material, and forming a second layer of material over the first layer and the patterned sacrificial material, which is then removed to form an encapsulated cavity. Ideally, the first and second layers are formed of the same type material. A structural support layer can be added to the second layer. Openings can be formed in the cavity, and the cavities can be layered side by side, vertically stacked with interconnections via the openings, and a combination of both can be used to construct stacked arrays with interconnections throughout.Type: ApplicationFiled: May 24, 2006Publication date: November 29, 2007Applicant: STMicroelectronics, Inc.Inventors: Frank Bryant, Murray Robinson
-
Publication number: 20070157330Abstract: Reconstituted human breast tumor models are disclosed. The models, which are incorporated into mice, provide actual tumors that arise spontaneously, thereby mimicking naturally occurring breast cancer. The tumors are genetically human, because they arise from human mammary tissues that develop from human mammary epithelial cells implanted into host mice. Prior to implantation, the mammary epithelial cells are genetically modified to contain either: (a) a recombinant human oncogene and an SV40er; or (b) a recombinant human oncogene, a transgene or shRNA that inhibits the p53 pathway, and a transgene or shRNA that inhibits the Rb pathway.Type: ApplicationFiled: March 8, 2007Publication date: July 5, 2007Inventors: Min Wu, Charlotte Kuperwasser, Murray Robinson
-
Publication number: 20060228302Abstract: A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary and sufficient for the tumorigenicity of the tumorigenic mouse cell, and (ii) the inducible promoter is in the uninduced state; and (b) introducing into the cell a recombinant gene of interest that functionally complements the oncogene, thereby restoring tumorigenicity without expression of the inducible recombinant oncogene. Also disclosed is a method of testing a compound for anti-tumor effects.Type: ApplicationFiled: April 5, 2006Publication date: October 12, 2006Inventors: Murray Robinson, Ronan O'Hagan, Karuppiah Kannan, Ti Cai, Maria Chiu, Lorena Lerner, Jie Lin, Yinghui Zhou